Two Cures in One Day
On December 8, 2023, the U.S. Food and Drug Administration did something unprecedented: it approved two gene therapies for sickle cell disease on the same day. Casgevy (exagamglogene autotemcel), developed by Vertex Pharmaceuticals and CRISPR Therapeutics, became the first CRISPR-based therapy ever approved in the United States. Hours later, Lyfgenia (lovotibeglogene autotemcel), developed by bluebird bio, received its own approval using a completely different genetic approach.
For the roughly 100,000 Americans living with sickle cell disease — and millions more worldwide — the dual approval represented a watershed moment. For the first time, patients had not just one but two potentially curative options for a disease that has historically been undertreated, underfunded, and disproportionately borne by Black communities.
But the two therapies are far from identical. They differ in mechanism, safety profile, price, and commercial trajectory. More than two years after approval, one company is thriving while the other has essentially collapsed. Understanding why requires a close look at both the science and the business behind these treatments.
How Sickle Cell Disease Works
Sickle cell disease is caused by a single-letter mutation in the HBB gene, which encodes the beta-globin subunit of hemoglobin. The mutation causes hemoglobin molecules to polymerize under low-oxygen conditions, distorting red blood cells into rigid, crescent-shaped "sickles." These misshapen cells block small blood vessels, causing excruciating pain episodes called vaso-occlusive crises (VOCs), organ damage, stroke, and a significantly shortened lifespan.
The disease follows autosomal recessive inheritance — a person must inherit two copies of the mutated gene (one from each parent) to develop SCD. Carriers with one copy have sickle cell trait, which is generally asymptomatic and confers some protection against malaria, explaining why the mutation persists at high frequency in populations with historical malaria exposure.
For decades, the only cure was a bone marrow transplant from a matched sibling donor — an option available to fewer than 20% of patients. The standard of care otherwise involved hydroxyurea, blood transfusions, and pain management. Casgevy and Lyfgenia promised to change that calculus entirely.
Casgevy: CRISPR Gene Editing
Casgevy takes an indirect but elegant approach. Rather than fixing the sickle mutation itself, it reactivates fetal hemoglobin — a form of hemoglobin that humans naturally produce before birth but switch off shortly after.
Mechanism
The therapy uses CRISPR-Cas9 to edit a gene called BCL11A in the patient's own hematopoietic stem cells. BCL11A acts as a molecular switch that suppresses fetal hemoglobin (HbF) production in adults. By disrupting the erythroid-specific enhancer of BCL11A, Casgevy releases the brake on HbF production. The resulting flood of fetal hemoglobin prevents sickle hemoglobin (HbS) from polymerizing, effectively neutralizing the disease at its molecular root.
This is technically a gene knockout rather than a gene correction. The sickle mutation remains in the patient's DNA, but it no longer matters because fetal hemoglobin compensates for defective adult hemoglobin.
Developers
Casgevy was co-developed by Vertex Pharmaceuticals (Cambridge, MA) and CRISPR Therapeutics (Zug, Switzerland). Vertex holds the commercial rights and leads the manufacturing and market access strategy. CRISPR Therapeutics, co-founded by Nobel laureate Emmanuelle Charpentier, contributed the gene editing platform.
Price
Casgevy carries a list price of $2.2 million per patient.
Lyfgenia: Lentiviral Gene Addition
Lyfgenia takes a fundamentally different approach. Instead of editing an existing gene, it adds a new, functional gene to the patient's stem cells using a viral vector.
Mechanism
Lyfgenia uses a modified lentiviral vector (derived from HIV) to deliver a gene encoding a modified beta-globin called betaA-T87Q-globin. This anti-sickling beta-globin is designed to produce functional hemoglobin (designated HbAT87Q) that interferes with the polymerization of sickle hemoglobin. Unlike Casgevy's approach, the original sickle mutation and BCL11A remain untouched. Instead, the therapy adds a competing, functional hemoglobin to the mix.
Gene addition via lentiviral vectors is a well-established approach that predates CRISPR editing by many years. bluebird bio pioneered this technology and used the same basic platform for its beta-thalassemia therapy Zynteglo, which was approved in the EU in 2019 and the U.S. in 2022.
Developers
Lyfgenia was developed by bluebird bio (Somerville, MA), which specialized exclusively in gene therapy after spinning off its oncology assets into a separate company called 2seventy bio in 2021.
Price
Lyfgenia carries a list price of $3.1 million per patient — nearly $1 million more than Casgevy.
Head-to-Head Comparison
| Feature | Casgevy | Lyfgenia |
|---|---|---|
| Generic name | Exagamglogene autotemcel (exa-cel) | Lovotibeglogene autotemcel (lovo-cel) |
| Developer | Vertex / CRISPR Therapeutics | bluebird bio |
| Mechanism | CRISPR-Cas9 gene editing (BCL11A knockout) | Lentiviral gene addition (anti-sickling beta-globin) |
| Approach | Reactivates fetal hemoglobin | Adds functional adult hemoglobin |
| Approved indication | SCD in patients 12+ with recurrent VOCs | SCD in patients 12+ with recurrent VOCs |
| List price | $2.2 million | $3.1 million |
| Key trial | CLIMB SCD-121 | HGB-206 |
| VOC-free rate | 93.5% (29/31 patients, 12+ months) | 88% (28/32 patients, 6+ months) |
| Black box warning | No | Yes — hematologic malignancy risk |
| Conditioning regimen | Myeloablative (busulfan) | Myeloablative (busulfan) |
| Cell source | Autologous (patient's own stem cells) | Autologous (patient's own stem cells) |
| Hospitalization | ~30 days minimum | ~30 days minimum |
| FDA approval date | December 8, 2023 | December 8, 2023 |
Clinical Trial Results in Detail
Casgevy: CLIMB SCD-121
The pivotal trial for Casgevy enrolled 44 patients aged 12 to 35 with severe sickle cell disease, defined as at least two VOCs per year. Results submitted to the FDA showed:
- 29 of 31 evaluable patients (93.5%) were free of VOCs for at least 12 consecutive months after infusion
- Mean total hemoglobin increased to near-normal levels
- Fetal hemoglobin (HbF) rose to between 20% and 45% of total hemoglobin — well above the ~20% threshold considered therapeutically meaningful
- Most patients achieved HbF levels sufficient to prevent sickling within 3 to 6 months of infusion
- All 31 evaluable patients were free of hospitalizations for VOCs during the evaluation period
The durability data has been encouraging. At the American Society of Hematology (ASH) conferences in 2024 and 2025, Vertex presented follow-up data showing that VOC freedom and elevated HbF levels persisted for three or more years in the earliest-treated patients. No patient who achieved a response subsequently relapsed.
Lyfgenia: HGB-206
The pivotal trial for Lyfgenia enrolled 47 patients aged 12 to 50 with severe SCD. The primary efficacy population for the FDA review included patients from the refined manufacturing process (Group C):
- 28 of 32 evaluable patients (88%) achieved complete resolution of VOCs for at least 6 consecutive months
- Patients produced anti-sickling hemoglobin (HbAT87Q) at levels ranging from 3 to 9 g/dL
- Total hemoglobin levels improved significantly, though the proportion of anti-sickling hemoglobin varied more widely between patients compared to Casgevy's more consistent HbF elevation
- Improvements in hemolysis markers confirmed reduced red blood cell destruction
While the efficacy numbers for Lyfgenia are strong, they are modestly lower than Casgevy's by most measures, and the evaluation window was shorter (6 months vs. 12 months VOC-free). This difference has factored into clinical decision-making.
The Safety Question: Blood Cancer and the Black Box Warning
The most significant differentiator between the two therapies is safety — specifically, the risk of hematologic malignancy.
Lyfgenia's Cancer Signal
In the HGB-206 trial, two patients developed blood cancer following treatment with Lyfgenia. One patient developed acute myeloid leukemia (AML) and another developed myelodysplastic syndrome (MDS). Both cases were potentially linked to the lentiviral vector's mechanism of action.
Lentiviral vectors integrate their genetic payload into the host cell's DNA in a semi-random fashion. While the vectors used in Lyfgenia are self-inactivating (SIN) designs meant to minimize the risk of activating nearby cancer-promoting genes, integration near oncogenes can still occur. This phenomenon — called insertional oncogenesis — was the central safety concern that plagued early gene therapy trials in the 2000s and has never been fully eliminated from integrating vector platforms.
As a result, the FDA required Lyfgenia to carry a black box warning — the most serious safety warning the agency can mandate — for hematologic malignancy. The label recommends lifelong monitoring for blood cancers in all Lyfgenia recipients.
bluebird bio has argued that the myeloablative conditioning with busulfan (required for both therapies) may have contributed to these cancers, since busulfan is itself a known carcinogen. Independent hematologists have noted that sickle cell patients in general have an elevated baseline risk of hematologic malignancies. However, the FDA attributed the signal specifically to Lyfgenia's lentiviral vector insertion.
Casgevy's Safety Profile
Casgevy does not carry a black box warning. CRISPR-Cas9 editing does not involve integrating foreign DNA into the genome. Instead, it makes a targeted cut at the BCL11A enhancer, which the cell repairs through its natural DNA repair mechanisms. The theoretical risks of CRISPR editing — off-target cuts at unintended genomic locations — have not materialized into clinical safety signals in Casgevy trials.
The most significant adverse events with Casgevy were related to the myeloablative conditioning rather than the gene editing itself: prolonged low blood counts, infections during the engraftment period, and the general toxicity of high-dose busulfan chemotherapy. These same conditioning-related risks apply equally to Lyfgenia.
For many physicians and patients, the absence of a cancer signal with Casgevy has been decisive. When both therapies require the same grueling preparation and hospitalization, the product without a black box warning for blood cancer holds an obvious advantage.
The Treatment Process: What Patients Go Through
Despite their different mechanisms, Casgevy and Lyfgenia impose a remarkably similar treatment journey on patients. Both are one-time therapies that require months of medical commitment.
Shared Steps
-
Evaluation and mobilization (weeks 1-8): Patients undergo extensive screening. Stem cell mobilization with plerixafor helps push stem cells from the bone marrow into the bloodstream for collection.
-
Apheresis (1-2 sessions): Blood is drawn and passed through a machine that separates out CD34+ hematopoietic stem cells. Enough cells must be collected for both the manufactured product and a backup supply.
-
Manufacturing (4-6 months for Casgevy; variable for Lyfgenia): The collected cells are shipped to a manufacturing facility. For Casgevy, CRISPR-Cas9 editing is performed. For Lyfgenia, cells are transduced with the lentiviral vector. Quality control and release testing add weeks to the timeline. Some early Lyfgenia patients experienced manufacturing failures requiring re-collection.
-
Myeloablative conditioning (~4 days): Once the product is ready, the patient is admitted for high-dose busulfan chemotherapy, which destroys their existing bone marrow. This is the most dangerous phase — patients become severely immunocompromised and require protective isolation.
-
Infusion (day 0): The modified stem cells are infused intravenously, similar to a standard stem cell transplant.
-
Engraftment and recovery (2-6 weeks inpatient, months outpatient): Patients remain hospitalized for a minimum of roughly 30 days while the edited or transduced cells engraft and begin producing new blood cells. Full hematologic recovery takes months.
-
Long-term follow-up: Both therapies require 15 years of post-treatment monitoring as a condition of their FDA approval.
Key Differences
The manufacturing process differs substantially. CRISPR editing is a more standardized and potentially scalable process — the same guide RNA and Cas9 protein are used for every patient. Lentiviral vector production is more complex and batch-dependent, with greater variability in transduction efficiency. bluebird bio experienced notable manufacturing challenges with its earlier product Zynteglo, and similar issues affected some Lyfgenia patients.
Vertex has invested heavily in authorized treatment centers (ATCs) and has established a larger network of qualified sites across the United States and Europe. bluebird bio, constrained by its financial difficulties, has been slower to expand its treatment center network.
The bluebird bio Collapse
Perhaps the most remarkable subplot of this story is the commercial failure of bluebird bio despite holding three FDA-approved gene therapies — a feat no other company had achieved at the time.
In addition to Lyfgenia, bluebird bio gained approval for Zynteglo (for transfusion-dependent beta-thalassemia, approved August 2022) and Skysona (for cerebral adrenoleukodystrophy, approved September 2022). Three approved gene therapies in roughly 13 months should have made the company a dominant force in genetic medicine.
Instead, bluebird bio faced a cascade of problems:
-
Pricing resistance: At $2.8 million for Zynteglo and $3.0 million for Skysona, payers pushed back hard. Lyfgenia at $3.1 million faced the same resistance, compounded by Casgevy's lower price point.
-
Slow uptake: Gene therapy requires specialized treatment centers, months of patient preparation, and complex logistics. The patient pipeline moved far slower than bluebird bio's financial models assumed. By mid-2024, only a handful of patients had been treated with any of the three products.
-
Manufacturing complexity: Lentiviral vector manufacturing is expensive, time-consuming, and prone to failures. Each patient's cells must be individually processed, with no economies of scale.
-
The cancer signal: Lyfgenia's black box warning made physicians and patients hesitant, especially with Casgevy available as an alternative.
-
Cash burn: bluebird bio was spending hundreds of millions per year on manufacturing infrastructure, commercial operations for three products, and ongoing clinical commitments while revenue trickled in.
In mid-2024, reports emerged that bluebird bio was exploring strategic alternatives. By late 2024, the situation had deteriorated further. In early 2025, the company announced it would be acquired and taken private for approximately $30 million — a staggering collapse for a company that had once held a market capitalization exceeding $10 billion. Three approved gene therapies, years of pioneering science, and billions in cumulative R&D spending reduced to a transaction value less than the price of treating ten patients with its own products.
The bluebird bio story has become a cautionary tale for the entire gene therapy industry about the gap between regulatory approval and commercial viability.
Which One Do Doctors Prefer?
Among hematologists treating sickle cell disease, Casgevy has emerged as the clear frontrunner. Several factors drive this preference:
-
No black box warning: The absence of a hematologic malignancy signal is the single most cited factor. Physicians treating a predominantly young patient population are reluctant to introduce even a small cancer risk when an alternative exists without one.
-
Stronger and more consistent efficacy: Casgevy's 93.5% VOC-free rate over 12 months edges out Lyfgenia's 88% over 6 months. The consistency of fetal hemoglobin elevation with Casgevy is also viewed favorably compared to the more variable HbAT87Q production with Lyfgenia.
-
Lower price: A $900,000 difference matters, even in the context of multi-million dollar therapies. It affects insurer willingness to approve and reduces the administrative burden of securing coverage.
-
Manufacturing reliability: Vertex's more streamlined manufacturing process and broader treatment center network translate to shorter wait times and fewer logistical obstacles for patients.
-
Company stability: Vertex is a large, profitable pharmaceutical company (driven primarily by its cystic fibrosis franchise) with the resources to sustain long-term manufacturing, patient support programs, and post-market commitments. bluebird bio's financial instability raised concerns about continuity of care and long-term follow-up obligations.
That said, some physicians note that Lyfgenia may remain relevant for specific patients. Because it uses a gene addition strategy targeting adult beta-globin rather than fetal hemoglobin, Lyfgenia could theoretically offer benefits for patients who have certain genetic variants affecting fetal hemoglobin regulation. In practice, however, these cases are rare, and most clinicians default to Casgevy.
Patient Decision Factors
For patients and families weighing the two options, several practical considerations come into play beyond the clinical data:
-
Risk tolerance: The blood cancer risk with Lyfgenia, even if small, is a deal-breaker for many patients and families. Sickle cell patients are disproportionately young — the median age at treatment in trials was early twenties — and the prospect of a lifetime cancer monitoring requirement is daunting.
-
Insurance coverage: Both therapies require prior authorization and often extensive appeals. Some insurers have preferred one over the other based on internal formulary decisions. The CMS model (discussed below) has helped standardize access for Medicaid patients.
-
Treatment center proximity: Not all authorized treatment centers offer both products. Geography can dictate the choice, particularly for patients in rural areas or states with fewer qualified centers.
-
Wait times: Manufacturing timelines differ, and treatment center capacity varies. Some patients have chosen the therapy with the shorter anticipated timeline to treatment.
-
Trust in the developer: Vertex's financial stability versus bluebird bio's uncertain future has influenced some families concerned about long-term support and follow-up.
The CMS Cell and Gene Therapy Access Model
Recognizing that Medicaid covers a disproportionate share of sickle cell patients — roughly half of all SCD patients in the U.S. are on Medicaid — the Centers for Medicare and Medicaid Services (CMS) launched the Cell and Gene Therapy (CGT) Access Model in January 2025.
The model is designed to address the central paradox of gene therapy pricing: these are one-time treatments with curative potential that justify high prices from a lifetime cost perspective, but their upfront costs create acute budget crises for state Medicaid programs.
Under the CGT Access Model:
- CMS negotiates national supplemental rebates with manufacturers on behalf of participating state Medicaid programs, achieving discounts beyond standard Medicaid rebates
- Both Casgevy and Lyfgenia are covered under the model
- Outcomes-based components tie a portion of the payment to whether patients achieve and maintain defined clinical outcomes (such as sustained freedom from VOCs)
- Participating states receive federal support for the administrative and clinical infrastructure required to deliver gene therapies
As of early 2026, the majority of U.S. states have opted into the model. The negotiated prices have not been publicly disclosed, but analysts estimate effective discounts of 30-50% off list price, bringing the real cost of Casgevy closer to $1.1-1.5 million and Lyfgenia to $1.5-2.1 million for Medicaid patients.
The CMS model represents the most significant government effort to date to ensure equitable access to gene therapies. It directly addresses the concern that these treatments — developed partly through publicly funded research — would be available only to the privately insured and the wealthy.
What This Comparison Tells Us About Gene Therapy's Future
The Casgevy-Lyfgenia comparison offers several lessons for the broader field of genetic medicine.
CRISPR editing may have structural advantages over gene addition for many diseases. CRISPR's precision, the avoidance of insertional mutagenesis risk, and more standardized manufacturing give it an edge that is likely to carry over into future head-to-head comparisons.
Price matters, even for curative therapies. The assumption that payers will accept any price for a one-time cure has been decisively disproven. bluebird bio priced itself out of the market not because its therapies were ineffective, but because it set prices higher than its competitor without a compensating safety or efficacy advantage.
Regulatory approval is necessary but not sufficient. Three FDA approvals did not save bluebird bio. The gene therapy field must solve manufacturing scalability, patient identification and referral logistics, payer negotiation, and treatment center buildout simultaneously — not sequentially.
Safety signals are commercially devastating. Even when a cancer risk is small and potentially attributable to confounding factors like busulfan conditioning, a black box warning in a competitive market is extremely difficult to overcome.
Government access models will be essential. Without programs like the CMS CGT Access Model, gene therapies risk becoming medical breakthroughs that only benefit a fraction of eligible patients. The sickle cell population — predominantly Black, disproportionately on Medicaid, historically underserved — is the ultimate test case for whether American health policy can deliver on the promise of precision medicine.
Looking Ahead
As of early 2026, Casgevy has treated an estimated several hundred patients in the United States and Europe, with the number growing as more treatment centers come online and the CMS model facilitates Medicaid access. Vertex has reported continued strong durability data, with no relapses observed in patients followed for three or more years.
Lyfgenia's future is uncertain. The acquisition of bluebird bio has raised questions about whether the new owners will continue to actively commercialize all three gene therapies or allow some to quietly fade from the market. Patients who have already received Lyfgenia will need the 15-year follow-up monitoring mandated by the FDA regardless of the company's fate, and the long-term safety data from these patients will be critical for the gene therapy field.
Meanwhile, next-generation approaches are already in development. Base editing therapies for sickle cell disease — which make precise single-letter changes without creating double-strand DNA breaks — are in clinical trials and could offer an even more refined approach. In vivo gene therapies that would eliminate the need for bone marrow extraction, conditioning chemotherapy, and prolonged hospitalization are in preclinical development.
The story of Casgevy and Lyfgenia is ultimately a story about a pivotal transition in medicine. For the first time, we can offer genetic cures for a disease that has caused immense suffering for millennia. That both therapies work is remarkable. That one company thrived while another collapsed in the process is a reminder that scientific achievement and commercial success obey different laws.
Sources
- U.S. Food and Drug Administration. "FDA Approves Two Gene Therapies for Sickle Cell Disease." FDA News Release, December 8, 2023.
- Frangoul H, et al. "Exagamglogene Autotemcel for Severe Sickle Cell Disease." New England Journal of Medicine, 2024.
- Kanter J, et al. "Lovotibeglogene Autotemcel Gene Therapy for Sickle Cell Disease." New England Journal of Medicine, 2024.
- Vertex Pharmaceuticals. Casgevy Prescribing Information. 2023.
- bluebird bio. Lyfgenia Prescribing Information (includes Boxed Warning for Hematologic Malignancy). 2023.
- Centers for Medicare & Medicaid Services. "Cell and Gene Therapy Access Model." CMS Innovation Center, 2025.
- Locatelli F, et al. "Outcomes of Lentiviral Gene Therapy in Patients with Sickle Cell Disease: HGB-206 Trial Update." Presented at ASH Annual Meeting, 2024.
- Vertex Pharmaceuticals / CRISPR Therapeutics. "Casgevy Long-Term Follow-Up Data." Presented at ASH Annual Meeting, 2025.
- bluebird bio. "Strategic Alternatives Review and Going-Private Transaction." SEC Filing, 2025.
- Pew Charitable Trusts. "Gene Therapy Access and Medicaid: Policy Considerations for State Programs." 2024.
- Tisdale JF, et al. "Current Results and Future Prospects for Gene Therapies in Sickle Cell Disease." Blood, 2024.
- National Heart, Lung, and Blood Institute. "Sickle Cell Disease: Evidence-Based Management." NIH, 2024.
